Knowledge · GeneralInterleukin-6: receptor context, trans-signaling, and the limits of selective therapyHow IL-6 receptors, ADAM10/17 proteolysis, and JAK–STAT3 shape tissue responses, what olamkicept trials found, and why selectivity has limits.
Knowledge · NutritionResveratrol and immune signalling: STAT3, NF-κB and the contradictions of SIRT1STAT3, NF-κB and NAD⁺-dependent deacetylation; conflicting Th17/Treg findings, pharmacokinetics and positive and negative clinical trials.October 9, 2026
